KRAS and lung adenocarcinoma: A major breakthrough was achieved with the recent development of mutant-specific KRASG12C inhibitors (8), which covalently bind to the novel cysteine residue present in nearly half of all patients with KRAS-mutant lung adenocarcinoma (9).